Lamivudine: fading into the mists of time

Lamivudine: fading into the mists of time

Bibliographic Details
Main Authors:	Jonggi Choi, Young-Suk Lim
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2017-12-01
Series:	Clinical and Molecular Hepatology
Subjects:	Lamivudine Entecavir Nucleos(t)ide analogues
Online Access:	http://e-cmh.org/upload/pdf/cmh-2017-0110.pdf

Similar Items

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis
by: Cesar Henriquez-Camacho, et al.
Published: (2023-11-01)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Sang Kyung Jung, et al.
Published: (2015-03-01)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
by: Rajeswari Jayakumar, et al.
Published: (2012-01-01)

Post-liver transplant HBV infection (Review)
by: A. D. Nikogosova, et al.
Published: (2022-07-01)

Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma
by: Moon Haeng Hur, et al.
Published: (2021-11-01)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
by: EunYoung Ze, et al.
Published: (2014-09-01)

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
by: Joo An Hwang, et al.
Published: (2015-06-01)

Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation
by: Jianming Yang, et al.
Published: (2023-01-01)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
by: Hyun Young Woo, et al.
Published: (2020-07-01)

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
by: Kwan Sik Lee, et al.
Published: (2017-12-01)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
by: Hee-Jeong Jeon, et al.
Published: (2017-09-01)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
by: Hu Peng, et al.
Published: (2011-08-01)

<i>De novo</i> hepatitis B virus infection after liver transplantation
by: A. D. Nikogosova, et al.
Published: (2022-09-01)

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations
by: Tanno Hugo, et al.
Published: (2011-06-01)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
by: Zhang C, et al.
Published: (2016-03-01)

Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study
by: Ming-Lun Yeh, et al.
Published: (2016-11-01)

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss
by: I-Chin Wu, et al.
Published: (2021-05-01)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
by: Jung Gil Park, et al.
Published: (2015-09-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
by: Andrew Hill, et al.
Published: (2015-04-01)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
by: Joon Yeul Nam, et al.
Published: (2017-12-01)

Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection
by: Min Zhang, et al.
Published: (2018-06-01)

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights
by: Fabrizio Fabrizi, et al.
Published: (2023-02-01)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
by: Camila V Pereira, et al.
Published: (2016-04-01)

Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
by: Faydra I. Lieveld, et al.
Published: (2013-05-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
by: Jeong Han Kim, et al.
Published: (2016-06-01)

Chronic Hepatitis B Treatment: Current Perspectives on Telbivudine
by: Gian Paolo Caviglia, et al.
Published: (2017-12-01)

Hepatitis C Virus Reactivation in Anti-HCV Antibody-Positive Patients with Chronic Hepatitis B Following Anti-HBV Therapies
by: Yi-Tse Su, et al.
Published: (2022-08-01)

Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
by: Elisabetta Degasperi, et al.
Published: (2022-10-01)

Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients
by: Ching-Chung Lin, et al.
Published: (2016-01-01)

HBV-INFECTION DE NOVO AFTER ORTHOTOPIC LIVER TRANSPLANTATION: CLINICAL AND VIROLOGICAL CHARACTERISTICS, ASSESSMENT OF ANTIVIRUS THERAPY EFFECTIVENESS
by: O. I. Malomuzh, et al.
Published: (2012-09-01)

Detection of Hepatitis B Virus Drug Resistance Mutations by Pyrosequencing Method
by: Mehmet ÇİMENTEPE, et al.
Published: (2018-12-01)

The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
by: Jae Min Park, et al.
Published: (2021-09-01)

Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir
by: Juhee Won, et al.
Published: (2022-07-01)

Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01)

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
by: Jing Zhao, et al.
Published: (2023-03-01)